(PHR) Phreesia - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US71944F1066

Scheduling, Registration, Payments, Check-In, Analytics

Stock: Health Care Technology
Age 6.5y
MCap 988m
Avg Vol 963K (16.0M USD)
Beta 1.036
Volatility 52.87%

EPS (Earnings per Share)

EPS (Earnings per Share) of PHR over the last years for every Quarter: "2021-01": -0.1, "2021-04": -0.11, "2021-07": -0.33, "2021-10": -0.46, "2022-01": -0.7, "2022-04": -0.71, "2022-07": -0.61, "2022-10": -0.48, "2023-01": -0.43, "2023-04": -0.38, "2023-07": -0.34, "2023-10": -0.25, "2024-01": -0.21, "2024-04": -0.35, "2024-07": -0.31, "2024-10": 0.0367, "2025-01": 0.1848, "2025-04": 0.2259, "2025-07": 0.01, "2025-10": 0.3121,
EPS CAGR: 135.31%
EPS Trend: 94.0%
Last SUE: 1.52
Qual. Beats: 1

Revenue

Revenue of PHR over the last years for every Quarter: 2021-01: 41.808, 2021-04: 48.291, 2021-07: 51.007, 2021-10: 55.915, 2022-01: 58.02, 2022-04: 63.354, 2022-07: 67.867, 2022-10: 73.103, 2023-01: 76.586, 2023-04: 83.845, 2023-07: 85.83, 2023-10: 91.619, 2024-01: 95.005, 2024-04: 101.217, 2024-07: 102.115, 2024-10: 106.8, 2025-01: 109.681, 2025-04: 115.936, 2025-07: 117.255, 2025-10: 120.333,
Rev. CAGR: 21.47%
Rev. Trend: 98.1%
Last SUE: 0.13
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 52.9%
Value at Risk 5%th 81.3%
Relative Tail Risk -6.53%
Reward TTM
Sharpe Ratio -0.96
Alpha -58.23
CAGR/Max DD -0.35
Character TTM
Hurst Exponent 0.468
Beta 1.036
Beta Downside 0.768
Drawdowns 3y
Max DD 68.62%
Mean DD 37.11%
Median DD 38.21%

Description: PHR Phreesia January 16, 2026

Phreesia Inc. (NYSE: PHR) operates a SaaS-based platform that streamlines patient intake, scheduling, payment, and clinical communication for U.S. and Canadian healthcare providers. Its product suite spans mobile-first solutions (Phreesia Mobile), on-site self-service hardware (Phreesia Pads and Arrival Kiosks), and a web dashboard that integrates insurance verification, point-of-sale payments, and post-visit collections.

Recent filings show Phreesia’s annual recurring revenue grew ~22 % YoY to $210 million in FY 2024, while its gross margin stabilized near 78 %, reflecting the high-margin nature of SaaS. The company’s growth is tied to broader sector drivers: accelerated digitization of patient workflows post-COVID-19, consolidation among health systems that favor enterprise-wide intake solutions, and rising demand for flexible payment options as consumer-direct billing expands. However, churn remains a material risk; the latest disclosed net-revenue retention hovers around 92 %, indicating modest upside from existing accounts.

For a deeper, data-driven look at Phreesia’s valuation assumptions and scenario analysis, the ValueRay platform provides a granular breakdown of forward cash-flow metrics and comparable peer benchmarks.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income: -5.38m TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA 12.08 > 1.0
NWC/Revenue: 30.68% < 20% (prev 19.84%; Δ 10.84% < -1%)
CFO/TA 0.15 > 3% & CFO 61.4m > Net Income -5.38m
Net Debt (-102.9m) to EBITDA (26.4m): -3.89 < 3
Current Ratio: 2.44 > 1.5 & < 3
Outstanding Shares: last quarter (61.5m) vs 12m ago 6.22% < -2%
Gross Margin: 68.20% > 18% (prev 0.67%; Δ 6753 % > 0.5%)
Asset Turnover: 115.9% > 50% (prev 107.8%; Δ 8.09% > 0%)
Interest Coverage Ratio: -1.01 > 6 (EBITDA TTM 26.4m / Interest Expense TTM 2.24m)

Altman Z'' -12.15

A: 0.34 (Total Current Assets 240.9m - Total Current Liabilities 98.8m) / Total Assets 423.5m
B: -1.89 (Retained Earnings -800.5m / Total Assets 423.5m)
C: -0.01 (EBIT TTM -2.26m / Avg Total Assets 399.6m)
D: -7.76 (Book Value of Equity -800.2m / Total Liabilities 103.1m)
Altman-Z'' Score: -12.15= D

Beneish M -3.32

DSRI: 0.80 (Receivables 88.3m/96.5m, Revenue 463.2m/405.1m)
GMI: 0.98 (GM 68.20% / 67.14%)
AQI: 0.90 (AQ_t 0.38 / AQ_t-1 0.42)
SGI: 1.14 (Revenue 463.2m / 405.1m)
TATA: -0.16 (NI -5.38m - CFO 61.4m) / TA 423.5m)
Beneish M-Score: -3.32 = AA

ValueRay F-Score (Strict, 0-100) 59.88

1. Piotroski: 6.0pt
2. FCF Yield: 4.74%
3. FCF Margin: 9.05%
4. Debt/Equity: 0.01
5. Debt/Ebitda: -3.89
6. ROIC - WACC: -10.39%
7. RoE: -1.85%
8. Revenue Trend: 98.14%
9. EPS Trend: 94.00%

What is the price of PHR shares?

As of January 23, 2026, the stock is trading at USD 15.80 with a total of 1,100,128 shares traded.
Over the past week, the price has changed by -3.95%, over one month by -4.07%, over three months by -32.62% and over the past year by -41.95%.

Is PHR a buy, sell or hold?

Phreesia has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy PHR.
  • Strong Buy: 10
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the PHR price?

Issuer Target Up/Down from current
Wallstreet Target Price 29.2 84.6%
Analysts Target Price 29.2 84.6%
ValueRay Target Price 13 -17.8%

PHR Fundamental Data Overview January 20, 2026

P/E Forward = 18.4162
P/S = 2.1332
P/B = 3.0847
Revenue TTM = 463.2m USD
EBIT TTM = -2.26m USD
EBITDA TTM = 26.4m USD
Long Term Debt = 3.35m USD (from longTermDebt, last quarter)
Short Term Debt = 6.20m USD (from shortLongTermDebt, last quarter)
Debt = 3.48m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.9m USD (from netDebt column, last quarter)
Enterprise Value = 885.2m USD (988.1m + Debt 3.48m - CCE 106.4m)
Interest Coverage Ratio = -1.01 (Ebit TTM -2.26m / Interest Expense TTM 2.24m)
EV/FCF = 21.12x (Enterprise Value 885.2m / FCF TTM 41.9m)
FCF Yield = 4.74% (FCF TTM 41.9m / Enterprise Value 885.2m)
FCF Margin = 9.05% (FCF TTM 41.9m / Revenue TTM 463.2m)
Net Margin = -1.16% (Net Income TTM -5.38m / Revenue TTM 463.2m)
Gross Margin = 68.20% ((Revenue TTM 463.2m - Cost of Revenue TTM 147.3m) / Revenue TTM)
Gross Margin QoQ = 68.40% (prev 67.90%)
Tobins Q-Ratio = 2.09 (Enterprise Value 885.2m / Total Assets 423.5m)
Interest Expense / Debt = 23.70% (Interest Expense 826.0k / Debt 3.48m)
Taxrate = 16.66% (854.0k / 5.12m)
NOPAT = -1.88m (EBIT -2.26m * (1 - 16.66%)) [loss with tax shield]
Current Ratio = 2.44 (Total Current Assets 240.9m / Total Current Liabilities 98.8m)
Debt / Equity = 0.01 (Debt 3.48m / totalStockholderEquity, last quarter 320.3m)
Debt / EBITDA = -3.89 (Net Debt -102.9m / EBITDA 26.4m)
Debt / FCF = -2.45 (Net Debt -102.9m / FCF TTM 41.9m)
Total Stockholder Equity = 291.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.35% (Net Income -5.38m / Total Assets 423.5m)
RoE = -1.85% (Net Income TTM -5.38m / Total Stockholder Equity 291.3m)
RoCE = -0.77% (EBIT -2.26m / Capital Employed (Equity 291.3m + L.T.Debt 3.35m))
RoIC = -0.63% (negative operating profit) (NOPAT -1.88m / Invested Capital 300.7m)
WACC = 9.77% (E(988.1m)/V(991.6m) * Re(9.73%) + D(3.48m)/V(991.6m) * Rd(23.70%) * (1-Tc(0.17)))
Discount Rate = 9.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.50%
[DCF Debug] Terminal Value 62.69% ; FCFF base≈41.9m ; Y1≈27.5m ; Y5≈12.6m
Fair Price DCF = 4.83 (EV 188.4m - Net Debt -102.9m = Equity 291.3m / Shares 60.3m; r=9.77% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 94.00 | EPS CAGR: 135.3% | SUE: 1.52 | # QB: 1
Revenue Correlation: 98.14 | Revenue CAGR: 21.47% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-04-30): EPS=0.36 | Chg30d=+0.009 | Revisions Net=+3 | Analysts=8
EPS next Year (2027-01-31): EPS=1.56 | Chg30d=+0.044 | Revisions Net=+6 | Growth EPS=+33.2% | Growth Revenue=+15.1%

Additional Sources for PHR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle